國立虎尾科技大學 |

Small molecules in hematology

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Small molecules in hematology/ edited by Uwe M. Martens.
其他作者:	Martens, Uwe M.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	viii, 294 p. :digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Antineoplastic agents. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-91439-8
ISBN:	9783319914398

Small molecules in hematology
Small molecules in hematology[electronic resource] /edited by Uwe M. Martens. - 3rd ed. - Cham :Springer International Publishing :2018. - viii, 294 p. :digital ;24 cm. - Recent results in cancer research,v.2120080-0015 ;. - Recent results in cancer research ;v.196..

Imatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib.

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.

ISBN: 9783319914398

Standard No.: 10.1007/978-3-319-91439-8doiSubjects--Topical Terms:

581036
Antineoplastic agents.

LC Class. No.: RS431.A64 / S635 2018

Dewey Class. No.: 616.994061

Small molecules in hematology
LDR:02424nam a2200337 a 4500 001 928036
003 DE-He213
005 20190130163406.0
006 m d
007 cr nn 008maaau
008 190626s2018 gw s 0 eng d
020 $a 9783319914398 $q (electronic bk.)
020 $a 9783319914381 $q (paper)
024 7 $a 10.1007/978-3-319-91439-8 $2 doi
035 $a 978-3-319-91439-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RS431.A64 $b S635 2018
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RS431.A64 $b S635 2018
245 0 0 $a Small molecules in hematology $h [electronic resource] / $c edited by Uwe M. Martens.
250 $a 3rd ed.
260 $a Cham : $c 2018. $b Springer International Publishing : $b Imprint: Springer,
300 $a viii, 294 p. : $b digital ; $c 24 cm.
490 1 $a Recent results in cancer research, $x 0080-0015 ; $v v.212
505 0 $a Imatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib.
520 $a This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.
650 0 $a Antineoplastic agents. $3 581036
650 0 $a Hematology. $3 645254
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Oncology. $3 593951
700 1 $a Martens, Uwe M. $3 1207758
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Recent results in cancer research ; $v v.196. $3 882903
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-91439-8
950 $a Medicine (Springer-11650)